News
ASCO26: Verzenio gives hope of liposarcoma treatment advance
The SARCO41 study suggests Lilly's Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.
News
ASCO26: Could AL amyloidosis see a new crop of therapies?
Trials of AstraZeneca's anselamimab and Regeneron's Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.
News
ASCO26: DNA test could spare breast cancer patients chemo
Millions of women with a breast cancer diagnosis could safely avoid chemotherapy that would not be effective, thanks to a genomics test.
Patients
ASCO: War, disasters, policy compound cancer care challenges
A Friday ASCO session highlighted the challenges faced by cancer patients in situations of geopolitical crisis, as presenters called for more support.
Oncology
ASCO 26: Three strong Pfizer Phase 3s, with Johanna Bendell
Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
